^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
VB10.16
i
Other names: VB10.16
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nykode Therap
Drug class:
Immunostimulant
Related drugs:
17d
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (clinicaltrials.gov)
P2; Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Apr 2024
Combination therapy • Enrollment open • Trial initiation date • PD(L)-1 companion diagnostic • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16
5ms
KEYNOTE-E72: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=51, Recruiting, Nykode Therapeutics ASA | Initiation date: Sep 2023 --> Dec 2023
Trial initiation date • Metastases
|
PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma)
|
Keytruda (pembrolizumab) • VB10.16
5ms
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer (clinicaltrials.gov)
P2, N=52, Completed, Nykode Therapeutics ASA | Active, not recruiting --> Completed | Phase classification: P2a --> P2 | Trial completion date: Mar 2024 --> Nov 2023 | Trial primary completion date: Aug 2023 --> Nov 2023
Trial completion • Phase classification • Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tecentriq (atezolizumab) • VB10.16
7ms
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. (clinicaltrials.gov)
P2; N=130; Not yet recruiting; Sponsor:Nykode Therapeutics ASA
Combination therapy • New P2 trial • PD(L)-1 companion diagnostic • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
VENTANA PD-L1 (SP263) Assay
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • VB10.16
7ms
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=51, Recruiting, Nykode Therapeutics ASA | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • VB10.16
9ms
KEYNOTE-E72: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P1/2, N=51, Not yet recruiting, Nykode Therapeutics ASA
New P1/2 trial • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Keytruda (pembrolizumab) • VB10.16
9ms
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer (clinicaltrials.gov)
P2a, N=50, Active, not recruiting, Nykode Therapeutics ASA | Trial primary completion date: Mar 2023 --> Aug 2023
Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • VB10.16
2years
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer (clinicaltrials.gov)
P2a, N=50, Active, not recruiting, Nykode Therapeutics AS | Recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Mar 2024 | Trial primary completion date: May 2022 --> Mar 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • VB10.16
almost4years
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer (clinicaltrials.gov)
P2a; N=50; Recruiting; Sponsor: Vaccibody AS; Not yet recruiting --> Recruiting
Enrollment open • Clinical
|
PD-L1 (Programmed death ligand 1)
|
Tecentriq (atezolizumab) • VB10.16
Share via
